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OBJECTIVES We sought to evaluate whether fasting hyperhomocystinemia reduces endothelial function by
oxidative stress in normotensive subjects and hypertensive patients.
BACKGROUND Subjects with hyperhomocystinemia have endothelial dysfunction.
METHODS In 23 normotensive subjects and 28 hypertensive patients, classified into normohomocystine-
mic and hyperhomocystinemic groups according to homocysteine plasma levels (,8.7 and
.14.6 mmol/l, respectively), we studied forearm blood flow changes (strain-gauge plethys-
mography) induced by intrabrachial administration of acetylcholine (0.15 to 15 mg/100 ml
tissue per min) or sodium nitroprusside (1 to 4 mg/100 ml per min), an endothelium-
dependent and -independent vasodilator, respectively. Acetylcholine was repeated with
N G-monomethyl-L-arginine (L-NMMA; 100 mg/100 ml per min), vitamin C (8 mg/100 ml
per min) and L-NMMA plus vitamin C.
RESULTS Normotensive hyperhomocystinemic patients showed a blunted response to acetylcholine and
a lower inhibiting effect of L-NMMA on acetylcholine, as compared with normohomo-
cystinemic patients. Although vitamin C was ineffective in normohomocystinemic subjects, it
increased the response to acetylcholine and restored the inhibiting effect of L-NMMA on
acetylcholine in hyperhomocystinemic patients. Hypertensive hyperhomocystinemic patients
showed a reduced response to acetylcholine, as compared with normohomocystinemic
subjects. In both subgroups, L-NMMA failed to blunt the response to acetylcholine. The
potentiating effect of vitamin C on acetylcholine was greater in hyperhomocystinemic patients
than in normohomocystinemic subjects, although it restored the inhibitory effect of
L-NMMA on acetylcholine-induced vasodilation to the same extent in both groups.
Hyperhomocystinemia did not change the response to sodium nitroprusside.
CONCLUSIONS In normotensive subjects and hypertensive patients, hyperhomocystinemia impairs
endothelium-dependent vasodilation. It could be related to oxidant activity. (J Am Coll
Cardiol 2001;38:1106–15) © 2001 by the American College of Cardiology
Homocysteine is a sulfur-containing amino acid formed
during dietary methionine metabolism (1). Epidemiologic
evidence indicates that mild elevation of the plasma homo-
cysteine level is associated with an increased risk of athero-
sclerosis (2).
Endothelium plays a primary role in the modulation of
vascular tone and structure through production of the
relaxing factor nitric oxide (NO), which acts by protecting
the vessel wall from development of atherosclerosis and
thrombosis (3). A dysfunctioning endothelium, character-
ized by reduced NO availability induced by oxidative stress,
is indicated as an early event in the pathogenesis of
atherosclerosis (3). Experimental evidence indicates that
hyperhomocystinemia (H-HCY) may induce endothelial
injury (4).
Moreover, homocysteine increases oxidative stress in vitro
(1). Thus, the promotion of endothelial dysfunction
through oxidative stress could be one of the potential
physiopathologic mechanisms through which H-HCY may
lead to atherosclerotic cardiovascular damage. In humans,
concordant studies evaluating the effect of long-term fasting
H-HCY on endothelial function indicate that subjects with
mild H-HCY show impaired flow-mediated endothelium-
dependent dilation (5,6).
The mechanism through which fasting H-HCY exerts
this adverse effect on endothelial function has not yet been
evaluated. Moreover, patients with essential hypertension
are characterized by endothelial dysfunction caused by
reduced NO availability due to oxidative stress (7,8). At the
present time, the possible effect of an interaction between
H-HCY and essential hypertension on endothelial function
remains to be determined. Therefore, the aim of the present
study was to evaluate whether fasting H-HCY impairs
endothelium-dependent vasodilation by oxidative stress in
the forearm microcirculation of normotensive subjects. In
addition, we also evaluated whether H-HCY and essential
hypertension exert a synergistic adverse effect on endothelial
function.
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METHODS
Patients and homocysteine measurement. A total of 209
subjects were evaluated in our study. This study group
included 90 normotensive subjects (mean age 49.2 6 13
years; blood pressure [BP] 126.7 6 9.3/81.7 6 4.7 mm Hg,
homocysteine level 12.5 6 5.6 mmol/l) and 119 patients
with essential hypertension (age 49.4 6 10 years; BP
151.5 6 14.6/98.6 6 5.8 mm Hg, homocysteine level
13.1 6 8.0 mmol/l). Subjects with a smoking history (.5
cigarettes/day), hypercholesterolemia (total cholesterol
.200 mg/dl), diabetes mellitus and cardiac and/or other
major diseases were excluded. The protocol was approved by
the Ethical Committee of the University of Pisa, and all
patients gave written, informed consent to participate in the
study.
The subjects were defined as normal according to the
absence of a family history of essential hypertension and
elevated BP values (Table 1). Patients with essential hyper-
tension were recruited from among the newly diagnosed
cases in our outpatient clinic if they reported the presence of
positive family history of essential hypertension, whenever
supine arterial BP (after 10 min of rest) was consistently
.140/90 mm Hg (Table 1). Secondary forms of hyperten-
sion were excluded by routine diagnostic procedures. Any
pharmacologic treatment was discontinued for at least two
weeks before performing the study.
In each individual venous blood was sampled after an
overnight fast. For homocysteine, vitamin B12 and folate
measurements, blood was put into tubes containing EDTA,
placed on ice and immediately centrifugated. Samples were
stored at 270°C until analysis. Serum homocysteine was
measured by high-performance liquid chromatography (9),
and vitamin B12 and folate by radioimmunoassay (ICN
System).
According to previous evidence (5,6), H-HCY was de-
fined as a homocysteine concentration corresponding to the
75th percentile of fasting homocysteine from the entire
group of individuals recruited. In our study group of 209
individuals, the upper quartile of fasting homocysteine
concentrations corresponded to $14.6 mmol/l, with no
differences between normotensive subjects and hypertensive
patients. From this group, 48 individuals withheld their
consent to participate in the vascular study, and in 29
individuals, the experimental procedure was not performed
because of technical problems. After these exclusions, a
final group of 132 individuals (61 normotensive subjects and
71 hypertensive patients) was investigated. Finally, we
included 12 normotensive subjects and 16 hypertensive
patients with homocysteine levels in the upper quartile
($14.6 mmol/l), and 11 normotensive subjects and 12
hypertensive patients with homocysteine levels in the lower
quartile (#8.7 mmol/l) (Table 1).
Experimental procedure. Vascular reactivity was assessed
by the perfused forearm technique. Briefly, the brachial
artery was cannulated for drug infusion at systemically
ineffective rates, as well as intra-arterial BP and heart rate
monitoring. Forearm blood flow (FBF) was measured in
experimental and the contralateral forearm by strain-gauge
venous plethysmography. Circulation to the hand was
excluded 1 min before FBF measurement by inflating a
pediatric cuff around the wrist at suprasystolic BP. Details
on the method have already been published (7).
Abbreviations and Acronyms
BP 5 blood pressure
FBF 5 forearm blood flow
H-HCY 5 hyperhomocystinemia
L-NMMA 5 N G-monomethyl-L-arginine
NO 5 nitric oxide
SNP 5 sodium nitroprusside
Table 1. Clinical Characteristics of the Study Group









Age (years) 48.2 6 10.9 50.5 6 11.4 49.6 6 7.8 47.8 6 10.5
Gender (male/female) 8/3 8/4 8/4 11/5
SBP (mm Hg) 126.3 6 5.7 124.4 6 7.5 148.2 6 8.3* 148.3 6 8.7*
DBP (mm Hg) 80.7 6 2.5 80.7 6 2.9 99.2 6 3.6* 100.3 6 5.1*
Heart rate (beats/min) 66.4 6 5.4 67.7 6 4.8 70.8 6 6.7 68.4 6 5.1
BMI (kg/m2) 22.1 6 3.2 21.8 6 2.6 22.3 6 3.8 21.7 6 3.2
Total cholesterol (mg/dl) 182.9 6 14.1 191.5 6 14.1 197.0 6 12.2 199.2 6 20.0
HDL cholesterol (mg/dl) 45.4 6 8.1 43.5 6 3.5 45.0 6 6.2 42.5 6 8.8
LDL cholesterol (mg/dl) 112.0 6 24.6 116.5 6 10.2 119.3 6 12.8 123.4 6 14.3
Plasma glucose (mg/dl) 83.8 6 5.1 80.7 6 6.7 82.4 6 6.6 80.2 6 6.9
Plasma homocysteine (mmol/l) 7.5 6 1.1 26.7 6 6.3† 7.5 6 0.8 28.2 6 11.7†
Plasma folate (ng/ml) 6.2 6 2.4 4.4 6 2.1 6.4 6 1.8 5.1 6 1.9
Plasma vitamin B12 (pg/ml) 441.3 6 166 311.9 6 120 419.6 6 137.7 342.6 6 96.2
*p , 0.05 vs. normotensive subjects; †p , 0.01 vs. normohomocystinemic patients. Data are presented as the mean value 6 SEM or number of subjects.
BMI 5 body mass index; DBP 5 diastolic blood pressure; HDL 5 high density lipoprotein; H-HCY 5 hyperhomocystinemia; LDL 5 low density lipoprotein; N-HCY 5
normohomocystinemia; SBP 5 systolic blood pressure.
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Experimental design. Endothelium-dependent vasodila-
tion was estimated by a dose-response curve to intra-arterial
acetylcholine (Farmigea S.p.A., Pisa, Italy; cumulative
increase in infusion rates by 0.15, 0.45, 1.5, 4.5 and
15 mg/100 ml forearm tissue per min, 5 min each dose),
whereas endothelium-independent vasodilation was esti-
mated by intra-arterial sodium nitroprusside (SNP; Malesci,
Milan, Italy; cumulative increase by 1, 2 and 4 mg/100 ml
per min, 5 min each dose).
To evaluate the NO availability, acetylcholine was re-
peated under intra-arterial infusion of NG-monomethyl-L-
arginine (L-NMMA), an NO synthase inhibitor (Clinalfa
AG, La¨ufelfingen, Switzerland; 100 mg/100 ml per min)
(10). Because L-NMMA modifies blood flow, the effect of
acetylcholine in the presence of the NO clamp, which allows
assessment of endothelial agonists in the presence of NO
synthase blockade without changes in blood flow (11), was
also evaluated. Thus, after 10 min of L-NMMA infusion,
SNP was co-infused to neutralize the L-NMMA–induced
vasoconstriction and restore baseline FBF. Then, SNP and
L-NMMA were continued throughout the acetylcholine
infusion (NO clamp system). In preliminary cases, a dose-
ranging analysis was performed for SNP to identify the rate
at which this compound could reverse the constrictor effect
of L-NMMA (0.4 and 0.3 mg/100 ml tissue per min for
5 min in normotensive subjects and hypertensive patients,
respectively). Moreover, in an adjunct group of hypertensive
patients, prolonged infusion of a constant dose of SNP
indicated that steady-state FBF was obtained after 2 min
and remained at the restored baseline level up to 25 min of
SNP infusion, hence demonstrating the stability of the NO
clamp (data not shown).
To assess oxidative stress production, acetylcholine was
again repeated under intra-arterial administration of vita-
min C (Bracco, Milan, Italy; 8 mg/100 ml per min), an
antioxidant (12) that was previously validated at this infu-
sion rate in our experimental conditions (7). Finally, to
evaluate whether oxidative stress could determine a decrease
in NO availability, another dose-response curve to acetyl-
choline was repeated under simultaneous infusion of
L-NMMA and vitamin C. Vitamin C was started 10 min
before acetylcholine and continued throughout. After
10 min of L-NMMA before the infusion, the NO clamp
technique was repeated.
Experimental data have shown that NO can act as a
negative feedback modulator of NO synthase (13). There-
fore, to assess the possibility that SNP co-infusion could
change the inhibiting effect of L-NMMA in an adjunct
group of young healthy normohomocystinemic subjects
(n 5 6), we produced a dose-response curve to acetylcholine
during saline and during L-NMMA in the absence and
presence of SNP co-infusion. Finally, to assess whether
exogenous NO by SNP, per se, could affect the response to
acetylcholine, independently of NO synthase blockade, we
repeated a dose-response curve to acetylcholine under the
NO clamp technique by replacing L-NMMA with the
endothelium-independent vasoconstrictor noradrenaline
(150 ng/100 ml per min).
A 30-min washout period was allowed between each
dose-response curve, whereas a 60-min period was allowed
when L-NMMA was infused.
Data analysis. Because BP did not significantly change
during the study, data were analyzed in terms of changes in
FBF, and FBF increments were taken as evidence of local
vasodilation. The FBF analyses were performed by an
observer (A.V.) who had no knowledge of the homocysteine
plasma values. Differences between two mean values were
compared by use of the paired or unpaired Student t test, as
appropriate. Dose-response curves to acetylcholine and
SNP were analyzed by means of analysis of variance and
analysis of co-variance, as appropriate, for repeated mea-
sures, and the Scheffe´ test was applied for multiple compar-
isons. The determinants of vasodilation to acetylcholine and
SNP were assessed within the whole study group of nor-
motensive subjects and patients with essential hypertension
by means of univariate and multivariate linear regression
analyses of homocysteine, folate, vitamin B12, cholesterol
and glucose levels, age, gender and BP. The results are
expressed as the mean value 6 SEM.
RESULTS
The clinical characteristics were similar between normoho-
mocystinemic and hyperhomocystinemic individuals, within
both the normotensive and hypertensive groups (Table 1).
H-HCY and endothelium-dependent and -independent
vasodilation. Vasodilation to acetylcholine was significantly
(p , 0.01) blunted in patients with essential hypertension
(FBF from 3.4 6 0.4 to a maximum of 13.7 6 4.3 ml/
100 ml forearm tissue per min with the highest dose—an
increase of 303%), as compared with normotensive control
subjects (FBF from 2.8 6 0.3 to 15.3 6 3.9 ml/100 ml per
min—an increase of 446%), whereas the response to SNP
was similar in both groups (FBF from 3.4 6 0.4 to 17.7 6
2.6 [420%] and from 2.8 6 0.3 to 15.9 6 3.3 ml/100 ml per
min [467%] in hypertensive patients and normotensive
subjects, respectively; p 5 NS). Hyperhomocystinemic nor-
motensive individuals showed a blunted response to acetyl-
choline, as compared with normohomocystinemic subjects
(Table 2, Fig. 1). Similarly, hyperhomocystinemic patients
with essential hypertension showed a further significantly
blunted response to acetylcholine, as compared with both
hypertensive patients with normal homocysteine levels (Fig.
1), and hyperhomocystinemic normotensive individuals
(Table 2). In contrast, the response to SNP was not different
between normohomocystinemic and hyperhomocystinemic
individuals, in either the normotensive or hypertensive
group (Table 2, Fig. 1). Considering the entire group of 61
normotensive subjects and 71 essential hypertensive patients
who took part in the vascular study, on univariate analysis,
according to a linear regression, the homocysteine plasma
level was inversely correlated with vasodilation to acetylcho-
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line, expressed as the percent increase at the highest infusion
rate, both in normotensive subjects (r 5 20.73, p ,
0.00001) and hypertensive patients (r 5 20.57, p , 0.001)
(Fig. 2). In contrast, no correlation was found between the
homocysteine level and the response to SNP (normotensive
subjects: r 5 20.03, p 5 NS; hypertensive patients: r 5
20.07, p 5 NS). In both normotensive subjects and
hypertensive patients, no relationship was found between
the vascular response to acetylcholine and folate (r 5 0.2
and r 5 20.03, respectively; p 5 NS), vitamin B12 (r 5 0.2
and r 5 20.04, p 5 NS), total cholesterol (r 5 0.3 and r 5
20.08, p 5 NS), high density lipoprotein cholesterol (r 5
0.8 and r 5 0.16, p 5 NS), low density lipoprotein
cholesterol (r 5 0.2 and r 5 20.05, p 5 NS), glucose (r 5
0.04 and r 5 0.02, p 5 NS), age (r 5 0.2 and r 5 0.1, p 5
NS), systolic BP (r 5 0.07 and r 5 20.07, p 5 NS) and
diastolic BP (r 5 0.19 and r 5 20.14, p 5 NS). On
multivariate analysis, the maximal response to acetylcholine
was again inversely correlated with the homocysteine level,
in both normotensive subjects (R2 5 0.69, p , 0.0001)
and patients with essential hypertension (R2 5 0.51, p ,
0.01), independent of the effects of other variables. How-
ever, when the data from normotensive subjects were
considered together with data from patients with essential
hypertension on multivariate analysis (R2 5 0.55), we found
that homocysteine (p , 0.0001) and diastolic BP (p , 0.05)
were the significant determinants of the response to acetyl-
choline.
H-HCY and responses to L-NMMA and vitamin C. In
normotensive subjects with hyperhomocystinemia, the in-
hibiting effect exerted by L-NMMA on acetylcholine
(227.6%), although still present, was lower than that
observed in normohomocystinemic subjects (252.7%), as
compared with acetylcholine alone (Table 2, Fig. 3).
In contrast, in both subgroups of patients with essential
hypertension, L-NMMA infusion failed to affect vasodila-
tion to acetylcholine (2% in normohomocystinemic patients
vs. 2% in hyperhomocystinemic patients), as compared with
acetylcholine alone (Table 2, Fig. 4). In normotensive
subjects with normohomocystinemia, vitamin C did not
modify vasodilation to acetylcholine (1%), as compared with
acetylcholine alone. In contrast, the antioxidant significantly
increased the response to acetylcholine in the hyperhomo-
cystinemic subgroup (45%), as compared with acetylcholine
alone, and the maximal vasodilation to acetylcholine was no
longer different between the two subgroups (Table 2, Fig.
3). Finally, when the effect of L-NMMA was retested under
vitamin C administration, the NO synthase inhibitor did
not modify its inhibitory effect on acetylcholine in normo-
homocystinemic subjects (22%), as compared with acetyl-
choline with L-NMMA alone, although it increased the
inhibitory effect on acetylcholine in hyperhomocystinemic
subjects (244%), as compared with acetylcholine with
vitamin C alone. Therefore, with vitamin C, the inhibiting
effect of L-NMMA on acetylcholine was no longer different
between the two groups (Table 2, Fig. 3). In patients with
essential hypertension, the potentiating effect of vitamin C
on acetylcholine-induced vasodilation was significantly
greater in hyperhomocystinemic patients than in normoho-
mocystinemic patients (97% and 24%, respectively), as
compared with acetylcholine alone) (Table 2, Fig. 4).
Therefore, after vitamin C infusion, the maximal vasodila-
Table 2. Maximal Absolute (ml/100 ml tissue per min) and Percent Forearm Blood Flow Modifications Above Baseline During
Acetylcholine, SNP, L-NMMA and Vitamin C Infusion
Normotensive Subjects Hypertensive Patients
N-HCY (n 5 11) H-HCY (n 5 12) N-HCY (n 5 12) H-HCY (n 5 16)
Baseline 2.7 6 0.3 2.9 6 0.3 3.3 6 0.5 3.5 6 0.4
ACh (15 mg/100 ml21 per min21) 17.5 6 4.1* (551%) 12.9 6 1.7 (352%) 16.2 6 4.6* (389%) 11.9 6 1.6† (244%)
Baseline 2.8 6 0.2 2.8 6 0.4 3.3 6 0.5 3.4 6 0.3
SNP (4 mg/100 ml21 per min21) 16.7 6 4.4 (495%) 15.0 6 1.0 (441%) 17.4 6 2.8 (432%) 17.8 6 2.4 (419%)
Baseline 2.8 6 0.3 2.8 6 0.3 3.4 6 0.4 3.5 6 0.4
L-NMMA (100 mg/100 ml per min21) 1.7 6 0.3 1.6 6 0.3 2.4 6 0.4 2.4 6 0.3
L-NMMA 1 SNP (0.3 mg/100 ml21 per min21) 2.8 6 0.3 2.8 6 0.3 3.3 6 0.5 3.4 6 0.4
L-NMMA 1 SNP 1 ACh 10.3 6 2.8‡ (266%) 9.8 6 1.5§ (255%) 16.6 6 4.9 (397%) 11.9 6 2.9 (250%)
Baseline 2.7 6 0.2 2.8 6 0.2 3.3 6 0.5 3.4 6 0.4
Vitamin C (8 mg/100 mL21 per min21) 2.8 6 0.2 2.7 6 0.2 3.3 6 0.4 3.5 6 0.4
Vitamin C 1 ACh 18.1 6 2.7 (556%) 17.0 6 2.1§ (524%) 19.2 6 4.9§ (481%) 20.0 6 5.4‡ (480%)
Baseline 2.8 6 0.3 2.8 6 0.3 3.5 6 0.5 3.5 6 0.5
L-NMMA 1.7 6 0.3 1.6 6 0.3 2.5 6 0.5 2.4 6 0.3
L-NMMA 1 SNP 2.8 6 0.4 2.8 6 0.5 3.5 6 0.6 3.4 6 0.4
L-NMMA 1 SNP 1 vitamin C 2.8 6 0.3 2.8 6 0.3 3.5 6 0.5 3.4 6 0.5
L-NMMA 1 SNP 1 vitamin C 1 ACh 10.1 6 2.5 (261%) 10.8 6 2.4 (286%) 13.2 6 2.2 (277%) 13.0 6 1.9 (282%)
*p , 0.05 vs. H-HCY. †p , 0.05 vs. H-HCY normotensive individuals. ‡p , 0.0001 vs. ACh alone. §p , 0.01 vs. ACh alone. Data are presented as the mean value 6 SEM.
ACh 5 acetylcholine; L-NMMA 5 N G-monomethyl-L-arginine; SNP 5 sodium nitroprusside; other abbreviations as in Table 1.
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tion to acetylcholine was no longer different between
hyperhomocystinemic and normohomocystinemic patients.
Finally, under antioxidant infusion, the inhibiting effect
of L-NMMA on vasodilation to acetylcholine was re-
stored to the same extent in both hyperhomocystinemic and
normohomocystinemic hypertensive patients (Table 2,
Fig. 4).
A highly significant direct correlation between homo-
cystinemia and the potentiating effect of vitamin C on
acetylcholine was found in normotensive subjects (r 5 0.83,
p , 0.001) and patients with essential hypertension (r 5
0.82, p , 0.001).
In all patients, contralateral FBF did not significantly
change throughout the study (data not shown).
Effect of SNP on the vascular response to acetylcho-
line. In this adjunct group of healthy subjects, the
vasodilation to acetylcholine (FBF from 2.7 6 0.4 to
18.1 6 3.9 ml/100 ml per min) was significantly (p ,
0.0001) blunted by L-NMMA (FBF from 1.7 6 0.3 to
6.1 6 1.9 ml/100 ml per min). During NO clamping,
L-NMMA, again, blunted the vasodilation to acetylcho-
line (FBF at baseline: 2.8 6 0.3; FBF with L-NMMA:
1.7 6 0.3; FBF with L-NMMA plus SNP: 2.8 6 0.3;
FBF with L-NMMA plus SNP plus acetylcholine:
10.1 6 2.5 ml/100 ml per min). The percent inhibition of
L-NMMA on acetylcholine was similar in the absence
and presence of SNP co-infusion (54.6% and 54.3%,
respectively). Finally, the vasodilation to acetylcholine
Figure 1. Acetylcholine- and sodium nitroprusside (SNP)-induced increases in forearm blood flow (FBF) in normotensive subjects (top) and patients with
essential hypertension (bottom), classified into those with normohomocystinemia (N-HCY; open circles) and hyperhomocystinemia (H-HCY; solid
circles).
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with noradrenaline and SNP (FBF at baseline: 2.7 6 0.3;
FBF with noradrenaline: 1.8 6 0.4; FBF with noradren-
aline plus SNP: 2.7 6 0.3; FBF with noradrenaline plus
SNP plus acetylcholine: 17.9 6 3.5 ml/100 ml per min)
was similar to that observed with saline infusion.
DISCUSSION
The present study was designed to evaluate whether
fasting H-HCY impairs endothelium-dependent vasodila-
tion by producing oxidative stress in the forearm microcir-
culation of normotensive subjects. In addition, it was also
evaluated whether H-HCY and essential hypertension
exert a synergistic adverse effect on endothelial function
and, if so, whether this effect could be mediated by oxidative
stress. In normotensive hyperhomocystinemic subjects, the
vasodilation to acetylcholine was significantly reduced, as
compared with that in normohomocystinemic individuals,
an alteration specific for the endothelium, because the
vascular response to SNP was similar between the two
subgroups. In addition, when the whole group was analyzed,
the response to acetylcholine, but not to SNP, showed a
significant inverse correlation with plasma homocysteine
concentrations. The relationship between homocysteine and
Figure 2. Scatterplot of relationship between homocysteine (x axis) and maximal forearm blood flow response to acetylcholine (Ach; y axis) in normotensive
subjects (top) and patients with essential hypertension (bottom). VD 5 vasodilation.
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endothelium-dependent vasodilation appears to be linear,
demonstrating a continuous effect without a threshold value.
Therefore, these data extend to the forearm resistance
vessels, with previous studies demonstrating that fasting
H-HCY is associated with impaired endothelium-
dependent vasodilation in the conduit vessels of normoten-
sive subjects (5,6).
Mechanisms responsible for H-HCY–induced endothe-
lial dysfunction. We employed L-NMMA and vitamin C
to assess NO availability and oxidative stress, respectively.
The effect of L-NMMA on the response to acetylcholine
was assessed by the NO clamp technique, which allows
restoration of basal arterial flow with SNP infusion. Control
experiments demonstrate that SNP co-infusion has no
direct effect on vasodilation to acetylcholine. In hyperho-
mocystinemic normotensive subjects, the diminished re-
sponse to acetylcholine seems to be mediated by a reduction
in NO availability, because in this subgroup, the inhibiting
effect of L-NMMA on acetylcholine-induced vasodilation
was significantly blunted, as compared with that in normo-
homocystinemic subjects.
The finding that acetylcholine still exerts a vaso-
dilating effect in normohomocystinemic subjects receiving
L-NMMA, is attributable to the fact that this L-arginine
Figure 3. Acetylcholine-induced increase in forearm blood flow (FBF) during saline (open circles) or NG-monomethyl-L-arginine (L-NMMA) (solid
circles), in the absence (control) and presence of vitamin C in normohomocystinemic (N-HCY) and hyperhomocystinemic (H-HCY) normotensive
subjects.
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analogue is a competitive antagonist for NO synthase, and
the dose used is unable to completely abolish NO produc-
tion. However, we cannot exclude the alternative possibility
that mediators different from NO, such as the hyperpolar-
izing factor or prostacyclin, account for the vasodilation to
acetylcholine under NO synthase inhibition (3).
With regard to oxidative stress, in hyperhomocystinemic
subjects, vitamin C administration reversed the
homocysteine-induced endothelial dysfunction, because the
antioxidant improved both vasodilation to acetylcholine and
the inhibiting effect of L-NMMA on acetylcholine. It is
worth noting that under vitamin C administration, the
degree of vasodilation to acetylcholine and the inhibition
exerted by L-NMMA were no longer different from the
effects observed in normohomocystinemic subjects. Finally,
in the overall group of normotensive subjects, homocystine-
mia showed a direct correlation with the potentiating effect
of vitamin C on acetylcholine. Taken together, these results
seem to indicate that in normotensive subjects, H-HCY
impairs endothelium-dependent vasodilation by reducing
NO availability. This alteration could be caused by increased
oxidative stress in H-HCY. Such a hypothesis is in agree-
Figure 4. Acetylcholine-induced increase in forearm blood flow (FBF) during saline (open circles) or NG-monomethyl-L-arginine (L-NMMA) (solid
circles), in the absence (control) and presence of vitamin C in normohomocystinemic (N-HCY) and hyperhomocystinemic (H-HCY) patients with
essential hypertension.
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ment with in vitro studies showing that homocysteine
produces oxidative stress, represented, above all, by super-
oxide anions, which are known to inactivate NO (14).
Although not planned in the present study, we recognize
that it would be interesting to evaluate the effect of another
L-arginine derivative, L-NAME. Given its property of inhib-
iting both NO and superoxide production by NO synthase,
L-NAME should be able to provide information on the source
of oxidative stress and, likewise, on NO availability.
H-HCY–induced endothelial dysfunction and oxidative
stress. In humans, the relationship between oxidative stress
and H-HCY was previously examined, with conf1icting
results. Chambers et al. (15) and Kanani et al. (16) found
that, in healthy subjects, oral administration of vitamin C
prevented the decrease in flow-mediated vasodilation after
methionine loading. In contrast, Hanratty et al. (17) and
Chao et al. (18) reported no change in oxidative status (as
assessed by thiobarbituric acid–reactive substances and
phosphatidylcholine hydroperoxide, respectively) after me-
thionine loading. In addition, as far as fasting hyperhomo-
cystinemia is concerned, Blom et al. (19) reported that lipid
peroxidation (as assessed by thiobarbituric acid–reactive
substances) was not increased in homocystinuric patients. A
possible explanation for this discrepancy could be related to
the different tools employed to evaluate the production of
oxidative stress (vitamin C vs. plasma markers of lipid
peroxidation). In fact, the antioxidant effect of vitamin C
not only scavenges superoxide anions or inhibits low density
lipoprotein oxidation, but also spares intracellular glutathi-
one, which, together with vitamin C, is the primary regu-
lator of the intracellular redox state (20), whereas the
thiobarbituric acid–reactive substances are only systemic
markers of oxidative stress (21). It is important to point out,
however, that in our experimental conditions we can only
speculate that vitamin C acts on endothelial function as an
antioxidant, because we cannot exclude a different mechanism,
such as stimulation of NO production (22).
Essential hypertension and H-HCY. The present results
indicate a blunted response to acetylcholine, but not to SNP, in
hypertensive patients as compared with normotensive subjects,
thereby confirming (7,8) the presence of endothelial dysfunc-
tion in essential hypertension. Moreover, hyperhomocystine-
mic hypertensive patients showed a further reduced vasodila-
tion to acetylcholine, but not to SNP, as compared with
normohomocystinemic hypertensive patients and hyperhomo-
cystinemic normotensive subjects. Moreover, when the whole
group was analyzed, acetylcholine, but not SNP, was inversely
correlated with plasma homocysteine. It is worth noting that in
the hypertensive group, on multivariate analysis, BP was not
independently correlated with the maximal response to acetyl-
choline, thereby confirming a lack of interaction between these
two variables (23). Only when the entire group was considered
(normotensive subjects plus hypertensive patients) did diastolic
BP come into play as a significant determinant of the response
to acetylcholine. This finding was expected, given the inclusion
of two groups characterized by a larger range of BP values and
responses to acetylcholine.
Taken together, these data demonstrate a synergistic
adverse effect between essential hypertension and H-HCY
on endothelial function—a finding that is in agreement with
the documented additive effect of the simultaneous presence
of different cardiovascular risk factors (24–26) on endothe-
lial dysfunction.
However, the relationship between H-HCY and im-
paired endothelium-dependent vasodilation in hypertensive
patients is more complex. In patients with essential hyper-
tension, vasodilation to acetylcholine is resistant to L-NMMA,
independent of the dose of the NO synthase antagonist used
(27), because such patients are characterized by the presence of
an oxidative stress-induced reduction in NO availability (7).
Therefore, mediator(s) other than NO (possibly a hyperpolar-
izing factor) account for the vascular relaxing responses to
endothelial agonists (8). Thus, the profound reduction in
endothelium-dependent vasodilation to acetylcholine observed
in hypertensive patients with H-HCY cannot be explained by
a reduction in NO availability. In contrast, increased produc-
tion of oxidative stress seems to be responsible for the endo-
thelial dysfunction in hyperhomocystinemic hypertensive pa-
tients, because in this subgroup, the potentiating effect exerted
by vitamin C was significantly greater than that in patients
with normal homocysteine levels. It should be noted that with
vitamin C administration, the response to acetylcholine was no
longer different between hyperhomocystinemic and normoho-
mocystinemic hypertensive patients, and the inhibiting effect of
L-NMMA on acetylcholine was restored in both subgroups.
Moreover, in the whole group of patients with essential
hypertension, a highly significant direct correlation was found
between homocystinemia and the potentiating effect of vitamin
C on acetylcholine.
Overall, these results seem to indicate that in patients with
essential hypertension, H-HCY causes a further reduction in
endothelial function by exacerbating the production of oxida-
tive stress. Such augmented production of oxygen free radicals
seems to act by impairing the alternative endothelial pathways
that act as compensatory mechanisms for the reduced NO
availability that is characteristic of essential hypertension.
Administration of an antioxidant such as vitamin C can correct
oxidative stress-induced endothelial dysfunction in hyperten-
sive patients with either normal or increased homocysteine
plasma levels by restoring NO availability.
Conclusions. This study indicates that in the forearm
microcirculation of normotensive subjects, H-HCY impairs
endothelial function by producing oxidative stress that
reduces NO availability. Moreover, in patients with essen-
tial hypertension, H-HCY can lead to a further reduction in
endothelial function by exacerbating the production of
oxidative stress and, consequently, by impairing NO-
independent endothelial responses. This profound impact of
H-HCY on endothelial function in both healthy subjects
and patients with essential hypertension could be one of the
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possible mechanisms through which H-HCY can lead to an
increased risk of cardiovascular disease.
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